

Gary R Cutter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6441995/publications.pdf>

Version: 2024-02-01

590
papers

35,124
citations

3159

92
h-index

5394

164
g-index

610
all docs

610
docs citations

610
times ranked

28977
citing authors

#	ARTICLE	IF	CITATIONS
1	Defining the clinical course of multiple sclerosis. <i>Neurology</i> , 2014, 83, 278-286.	1.1	2,344
2	Cardia: study design, recruitment, and some characteristics of the examined subjects. <i>Journal of Clinical Epidemiology</i> , 1988, 41, 1105-1116.	5.0	1,409
3	Individual and Combined Effects of Age, Breast Density, and Hormone Replacement Therapy Use on the Accuracy of Screening Mammography. <i>Annals of Internal Medicine</i> , 2003, 138, 168.	3.9	960
4	The prevalence of MS in the United States. <i>Neurology</i> , 2019, 92, e1029-e1040.	1.1	765
5	Randomized Trial of Thymectomy in Myasthenia Gravis. <i>New England Journal of Medicine</i> , 2016, 375, 511-522.	27.0	695
6	Relation of Visual Function to Retinal Nerve Fiber Layer Thickness in Multiple Sclerosis. <i>Ophthalmology</i> , 2006, 113, 324-332.	5.2	589
7	Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn. <i>Journal of Pediatrics</i> , 1997, 131, 55-62.	1.8	531
8	Influence of Computer-Aided Detection on Performance of Screening Mammography. <i>New England Journal of Medicine</i> , 2007, 356, 1399-1409.	27.0	504
9	Detection of Ductal Carcinoma In Situ in Women Undergoing Screening Mammography. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1546-1554.	6.3	503
10	Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOMentum): a double-blind, randomised placebo-controlled phase 2/3 trial. <i>Lancet</i> , The, 2019, 394, 1352-1363.	18.7	483
11	Effect of relapses on development of residual deficit in multiple sclerosis. <i>Neurology</i> , 2003, 61, 1528-1532.	1.1	394
12	The incidence and prevalence of psychiatric disorders in multiple sclerosis: A systematic review. <i>Multiple Sclerosis Journal</i> , 2015, 21, 305-317.	3.0	381
13	Risk of Serious Injury for Young Baseball Pitchers. <i>American Journal of Sports Medicine</i> , 2011, 39, 253-257.	4.2	357
14	Early Inhaled Nitric Oxide Therapy in Premature Newborns with Respiratory Failure. <i>New England Journal of Medicine</i> , 2006, 355, 354-364.	27.0	343
15	Recommendations from the national multiple sclerosis society clinical outcomes assessment task force. <i>Annals of Neurology</i> , 1997, 42, 379-382.	5.3	342
16	Long-term evolution of multiple sclerosis disability in the treatment era. <i>Annals of Neurology</i> , 2016, 80, 499-510.	5.3	331
17	Natural History of Multiple Sclerosis Symptoms. <i>International Journal of MS Care</i> , 2013, 15, 146-156.	1.0	328
18	Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. <i>Annals of Neurology</i> , 2010, 67, 749-760.	5.3	308

#	ARTICLE	IF	CITATIONS
19	Comparison of Full-Field Digital Mammography with Screen-Film Mammography for Cancer Detection: Results of 4,945 Paired Examinations. <i>Radiology</i> , 2001, 218, 873-880.	7.3	305
20	Optical coherence tomography: a window into the mechanisms of multiple sclerosis. <i>Nature Clinical Practice Neurology</i> , 2008, 4, 664-675.	2.5	282
21	A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview. <i>Multiple Sclerosis Journal</i> , 2015, 21, 263-281.	3.0	273
22	Interactions between cannabidiol and commonly used antiepileptic drugs. <i>Epilepsia</i> , 2017, 58, 1586-1592.	5.1	267
23	Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: a randomised controlled trial. <i>Lancet</i> , The, 1999, 354, 1061-1065.	13.7	265
24	Factors that influence adherence with disease-modifying therapy in MS. <i>Journal of Neurology</i> , 2009, 256, 568-576.	3.6	238
25	A Randomized, Controlled Trial of Very Early Prophylactic Ligation of the Ductus Arteriosus in Babies Who Weighed 1000 g or Less at Birth. <i>New England Journal of Medicine</i> , 1989, 320, 1511-1516.	27.0	237
26	Clinical Comparison of Full-Field Digital Mammography and Screen-Film Mammography for Detection of Breast Cancer. <i>American Journal of Roentgenology</i> , 2002, 179, 671-677.	2.2	235
27	Recruitment in the Coronary Artery Disease Risk Development in Young Adults (Cardia) study. <i>Contemporary Clinical Trials</i> , 1987, 8, 68-73.	1.9	231
28	Persistent pain and uncomfortable sensations in persons with multiple sclerosis. <i>Pain</i> , 2007, 127, 35-41.	4.2	227
29	Cardiovascular risk factors in young adults. <i>Contemporary Clinical Trials</i> , 1991, 12, 1-77.	1.9	225
30	Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis. <i>JAMA Neurology</i> , 2021, 78, 699.	9.0	225
31	Intrauterine growth retardation and preterm delivery: prenatal risk factors in an indigent population. <i>American Journal of Obstetrics and Gynecology</i> , 1990, 162, 213-218.	1.3	224
32	Treatment for Mild Chronic Hypertension during Pregnancy. <i>New England Journal of Medicine</i> , 2022, 386, 1781-1792.	27.0	215
33	Prevalence odds ratio versus prevalence ratio: choice comes with consequences. <i>Statistics in Medicine</i> , 2016, 35, 5730-5735.	1.6	207
34	Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: A meta-analytic approach. <i>Annals of Neurology</i> , 2009, 65, 268-275.	5.3	206
35	Strategies for the Prevention of Early-Onset Neonatal Group B Streptococcal Sepsis. <i>Obstetrics and Gynecology</i> , 1994, 83, 483-494.	2.4	204
36	Mortality in patients with multiple sclerosis. <i>Neurology</i> , 2013, 81, 184-192.	1.1	199

#	ARTICLE	IF	CITATIONS
37	The Multiple Sclerosis Functional Composite: a new clinical outcome measure for multiple sclerosis trials. <i>Multiple Sclerosis Journal</i> , 2002, 8, 359-365.	3.0	198
38	Accuracy of Screening Mammography Interpretation by Characteristics of Radiologists. <i>Journal of the National Cancer Institute</i> , 2004, 96, 1840-1850.	6.3	196
39	Adjunctive Azithromycin Prophylaxis for Cesarean Delivery. <i>New England Journal of Medicine</i> , 2016, 375, 1231-1241.	27.0	192
40	The burden of mental comorbidity in multiple sclerosis: frequent, underdiagnosed, and undertreated. <i>Multiple Sclerosis Journal</i> , 2009, 15, 385-392.	3.0	191
41	A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. <i>Muscle and Nerve</i> , 2013, 48, 76-84.	2.2	187
42	Randomized study combining interferon and glatiramer acetate in multiple sclerosis. <i>Annals of Neurology</i> , 2013, 73, 327-340.	5.3	182
43	Association of Umbilical Cord Milking vs Delayed Umbilical Cord Clamping With Death or Severe Intraventricular Hemorrhage Among Preterm Infants. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1877.	7.4	182
44	Late results of surgical and medical therapy for patients with coronary artery disease and depressed left ventricular function. <i>Journal of the American College of Cardiology</i> , 1985, 5, 1036-1045.	2.8	178
45	Low-dose aspirin therapy to prevent preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 1993, 168, 1083-1093.	1.3	176
46	Alcohol intake and blood pressure in young adults: The CARDIA study. <i>Journal of Clinical Epidemiology</i> , 1990, 43, 1-13.	5.0	172
47	EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial. <i>Lancet, The</i> , 2014, 383, 1637-1647.	13.7	171
48	Comorbidity, socioeconomic status and multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008, 14, 1091-1098.	3.0	168
49	Macular Volume Determined by Optical Coherence Tomography as a Measure of Neuronal Loss in Multiple Sclerosis. <i>Archives of Neurology</i> , 2009, 66, 1366-72.	4.5	165
50	Defining reliable disability outcomes in multiple sclerosis. <i>Brain</i> , 2015, 138, 3287-3298.	7.6	162
51	Cigarette smoking behavior is strongly related to educational status: The cardia study. <i>Preventive Medicine</i> , 1990, 19, 158-169.	3.4	157
52	The Effect of Cigarette Smoking on Neonatal Anthropometric Measurements. <i>Obstetrics and Gynecology</i> , 1995, 85, 625-630.	2.4	155
53	Clinical outcomes assessment in multiple sclerosis. <i>Annals of Neurology</i> , 1996, 40, 469-479.	5.3	155
54	Infectious causes of multiple sclerosis. <i>Lancet Neurology, The</i> , 2006, 5, 887-894.	10.2	151

#	ARTICLE	IF	CITATIONS
55	Disability in multiple sclerosis. <i>Neurology</i> , 2013, 80, 1018-1024.	1.1	150
56	Less is more, or almost as much: A 15-item quality-of-life instrument for myasthenia gravis. <i>Muscle and Nerve</i> , 2008, 38, 957-963.	2.2	149
57	Diet quality is associated with disability and symptom severity in multiple sclerosis. <i>Neurology</i> , 2018, 90, e1-e11.	1.1	149
58	New low-contrast vision charts: reliability and test characteristics in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2000, 6, 163-171.	3.0	147
59	Acute kidney injury and renal replacement therapy independently predict mortality in neonatal and pediatric noncardiac patients on extracorporeal membrane oxygenation. <i>Pediatric Critical Care Medicine</i> , 2011, 12, e1-e6.	0.5	147
60	Molecular Transducers of Physical Activity Consortium (MoTrPAC): Mapping the Dynamic Responses to Exercise. <i>Cell</i> , 2020, 181, 1464-1474.	28.9	147
61	Intrauterine growth retardation: Standards for diagnosis. <i>American Journal of Obstetrics and Gynecology</i> , 1989, 161, 271-277.	1.3	142
62	Cell-based therapeutic strategies for multiple sclerosis. <i>Brain</i> , 2017, 140, 2776-2796.	7.6	139
63	Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. <i>Lancet Neurology</i> , The, 2019, 18, 259-268.	10.2	139
64	Inhaled Nitric Oxide in Preterm Infants: An Individual-Patient Data Meta-analysis of Randomized Trials. <i>Pediatrics</i> , 2011, 128, 729-739.	2.1	136
65	High frequency of adverse health behaviors in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009, 15, 105-113.	3.0	135
66	Comparative analysis of therapeutic options used for myasthenia gravis. <i>Annals of Neurology</i> , 2010, 68, 797-805.	5.3	135
67	Effect of Breast Augmentation on the Accuracy of Mammography and Cancer Characteristics. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 442.	7.4	134
68	Physician Predictors of Mammographic Accuracy. <i>Journal of the National Cancer Institute</i> , 2005, 97, 358-367.	6.3	132
69	A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 282-293.	3.0	131
70	A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 318-331.	3.0	131
71	Performance of Diagnostic Mammography for Women With Signs or Symptoms of Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1151-1159.	6.3	127
72	A randomized controlled study of the acute and chronic effects of cooling therapy for MS. <i>Neurology</i> , 2003, 60, 1955-1960.	1.1	127

#	ARTICLE	IF	CITATIONS
73	Prognostic Characteristics of Breast Cancer Among Postmenopausal Hormone Users in a Screened Population. <i>Journal of Clinical Oncology</i> , 2003, 21, 4314-4321.	1.6	127
74	Recommendations for myasthenia gravis clinical trials. <i>Muscle and Nerve</i> , 2012, 45, 909-917.	2.2	122
75	Preferred Sources of Health Information in Persons With Multiple Sclerosis: Degree of Trust and Information Sought. <i>Journal of Medical Internet Research</i> , 2013, 15, e67.	4.3	121
76	Short latency activation of cortex during clinically effective subthalamic deep brain stimulation for Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 864-873.	3.9	120
77	Psychological correlates of weight fluctuation. <i>International Journal of Eating Disorders</i> , 1995, 17, 263-275.	4.0	118
78	Outcomes of Endovascular Thrombectomy vs Medical Management Alone in Patients With Large Ischemic Cores. <i>JAMA Neurology</i> , 2019, 76, 1147.	9.0	118
79	Molecular subtypes of osteosarcoma identified by reducing tumor heterogeneity through an interspecies comparative approach. <i>Bone</i> , 2011, 49, 356-367.	2.9	117
80	Clinical Significance of the Multiple Sclerosis Functional Composite. <i>Archives of Neurology</i> , 2000, 57, 1319-24.	4.5	116
81	Retinal Imaging by Laser Polarimetry and Optical Coherence Tomography Evidence of Axonal Degeneration in Multiple Sclerosis. <i>Archives of Neurology</i> , 2008, 65, 924-8.	4.5	114
82	Issues in the natural history and treatment of coronary heart disease in black populations: Surgical treatment. <i>American Heart Journal</i> , 1984, 108, 688-694.	2.7	112
83	Validation of the NARCOMS registry: diagnosis. <i>Multiple Sclerosis Journal</i> , 2007, 13, 770-775.	3.0	111
84	Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study. <i>Epilepsy and Behavior</i> , 2018, 87, 131-136.	1.7	110
85	The Relationship Between Maternal Hematocrit and Pregnancy Outcome. <i>Obstetrics and Gynecology</i> , 1991, 77, 190-194.	2.4	109
86	Randomized Effectiveness Trial of a Computer-Assisted Intervention to Improve Diabetes Care. <i>Diabetes Care</i> , 2005, 28, 33-39.	8.6	105
87	Construction of an efficient evaluative instrument for Myasthenia Gravis: The MG composite. <i>Muscle and Nerve</i> , 2008, 38, 1553-1562.	2.2	105
88	Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. <i>Neurology</i> , 2019, 93, e1452-e1462.	1.1	104
89	Intracortical lesions by 3T magnetic resonance imaging and correlation with cognitive impairment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2011, 17, 1122-1129.	3.0	102
90	Prevalence and characteristics of tremor in the NARCOMS multiple sclerosis registry: a cross-sectional survey. <i>BMJ Open</i> , 2015, 5, e006714-e006714.	1.9	102

#	ARTICLE	IF	CITATIONS
91	Natalizumab-associated PML. <i>Neurology</i> , 2017, 88, 1197-1205.	1.1	102
92	A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 342-349.	3.0	100
93	Reproducibility of high-resolution optical coherence tomography in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 829-839.	3.0	98
94	Prematurity, postdates, and growth retardation: The influence of use of ultrasonography on reported gestational age. <i>American Journal of Obstetrics and Gynecology</i> , 1989, 160, 462-470.	1.3	94
95	Assessing changes in relapse rates in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1414-1421.	3.0	93
96	Clinical Electroencephalographic Biomarker for Impending Epilepsy in Asymptomatic Tuberculous Sclerosis Complex Infants. <i>Pediatric Neurology</i> , 2016, 54, 29-34.	2.1	93
97	The prospective relationships between smoking and weight in a young, biracial cohort: The Coronary Artery Risk Development in Young Adults study.. <i>Journal of Consulting and Clinical Psychology</i> , 1998, 66, 987-993.	2.0	92
98	Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 12, 70-78.	2.0	92
99	Association between Mammography Timing and Measures of Screening Performance in the United States. <i>Radiology</i> , 2005, 234, 363-373.	7.3	91
100	Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: An observational study using the US Department of Defense administrative claims database. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 546-554.	2.0	87
101	International clinimetric evaluation of the MGâ€œQOL15, resulting in slight revision and subsequent validation of the MGâ€œQOL15r. <i>Muscle and Nerve</i> , 2016, 54, 1015-1022.	2.2	85
102	COVID-19-associated risks and effects in myasthenia gravis (CARE-MG). <i>Lancet Neurology</i> , The, 2020, 19, 970-971.	10.2	85
103	Mammography Facility Characteristics Associated With Interpretive Accuracy of Screening Mammography. <i>Journal of the National Cancer Institute</i> , 2008, 100, 876-887.	6.3	84
104	No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsingâ€œRemitting Multiple Sclerosis. <i>Advances in Therapy</i> , 2014, 31, 1134-1154.	2.9	83
105	Mortality in neuromyelitis optica is strongly associated with African ancestry. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2018, 5, e468.	6.0	83
106	The Risk of Renal Calculi in Spinal Cord Injury Patients. <i>Journal of Urology</i> , 1984, 131, 857-859.	0.4	81
107	The Association Between Obesity and Screening Mammography Accuracy. <i>Archives of Internal Medicine</i> , 2004, 164, 1140.	3.8	80
108	A practical randomized trial to improve diabetes care. <i>Journal of General Internal Medicine</i> , 2004, 19, 1167-1174.	2.6	79

#	ARTICLE	IF	CITATIONS
109	A systematic review of the incidence and prevalence of cancer in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 294-304.	3.0	79
110	Mammography Screening and Differences in Stage of Disease by Race/Ethnicity. <i>American Journal of Public Health</i> , 2002, 92, 1144-1150.	2.7	78
111	Performance comparison of full-field digital mammography to screen-film mammography in clinical practice. <i>Medical Physics</i> , 2002, 29, 830-834.	3.0	76
112	Randomized Trial Testing a Worksite Sun Protection Program in an Outdoor Recreation Industry. <i>Health Education and Behavior</i> , 2005, 32, 514-535.	2.5	76
113	Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1. <i>Neurology</i> , 2016, 87, 2575-2584.	1.1	76
114	Influence of genetic background on tumor karyotypes: Evidence for breed-associated cytogenetic aberrations in canine appendicular osteosarcoma. <i>Chromosome Research</i> , 2009, 17, 365-377.	2.2	74
115	Accuracy of Blood Pressure Measurement Devices in Pregnancy. <i>Hypertension</i> , 2018, 71, 326-335.	2.7	74
116	Does Litigation Influence Medical Practice? The Influence of Community Radiologists' Medical Malpractice Perceptions and Experience on Screening Mammography. <i>Radiology</i> , 2005, 236, 37-46.	7.3	73
117	Testing the risk compensation hypothesis for safety helmets in alpine skiing and snowboarding. <i>Injury Prevention</i> , 2007, 13, 173-177.	2.4	73
118	Constraint-Induced Movement therapy can improve hemiparetic progressive multiple sclerosis. Preliminary findings. <i>Multiple Sclerosis Journal</i> , 2008, 14, 992-994.	3.0	73
119	Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis?. <i>Muscle and Nerve</i> , 2014, 49, 483-486.	2.2	73
120	Divergent effects of AKI to CKD models on inflammation and fibrosis. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 315, F1107-F1118.	2.7	73
121	Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 3446-3454.	1.6	73
122	Reproducibility of Optical Coherence Tomography in Multiple Sclerosis. <i>Archives of Neurology</i> , 2008, 65, 1218-22.	4.5	72
123	Regional cortical thickness in relapsing remitting multiple sclerosis: A multi-center study. <i>NeuroImage: Clinical</i> , 2013, 2, 120-131.	2.7	72
124	Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker. <i>Annals of Neurology</i> , 2021, 89, 895-910.	5.3	72
125	The Multiple Sclerosis Intimacy and Sexuality Questionnaire "re-validation and development of a 15-item version with a large US sample. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1197-1203.	3.0	71
126	<i>Status of the Thymectomy Trial for Nonthymomatous Myasthenia Gravis Patients Receiving Prednisone</i>. <i>Annals of the New York Academy of Sciences</i> , 2008, 1132, 344-347.	3.8	69

#	ARTICLE	IF	CITATIONS
127	A cross-sectional study of bone health in multiple sclerosis. <i>Neurology</i> , 2009, 73, 1394-1398.	1.1	69
128	Rates and Causes of Disagreement in Interpretation of Full-Field Digital Mammography and Film-Screen Mammography in a Diagnostic Setting. <i>American Journal of Roentgenology</i> , 2001, 176, 1241-1248.	2.2	67
129	Gene expression profiling identifies inflammation and angiogenesis as distinguishing features of canine hemangiosarcoma. <i>BMC Cancer</i> , 2010, 10, 619.	2.6	67
130	Randomized Trials on Consider This, a Tailored, Internet-Delivered Smoking Prevention Program for Adolescents. <i>Health Education and Behavior</i> , 2008, 35, 260-281.	2.5	66
131	Disability Progression in a Clinical Trial of Relapsing-Remitting Multiple Sclerosis. <i>Archives of Neurology</i> , 2010, 67, 1329-35.	4.5	65
132	Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , The, 2020, 19, 988-997.	10.2	64
133	Placebo-controlled study in neuromyelitis optica—Ethical and design considerations. <i>Multiple Sclerosis Journal</i> , 2016, 22, 862-872.	3.0	63
134	Factors that predict Health-Related Quality of Life in patients with relapsing -remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2003, 9, 1-5.	3.0	61
135	Physical Activity and Self-Reported Cardiovascular Comorbidities in Persons with Multiple Sclerosis: Evidence from a Cross-Sectional Analysis. <i>Neuroepidemiology</i> , 2011, 36, 183-191.	2.3	61
136	Warning symptoms, uterine contractions, and cervical examination findings in women at risk of preterm delivery. <i>American Journal of Obstetrics and Gynecology</i> , 1990, 162, 748-754.	1.3	60
137	Unilateral subthalamic nucleus deep brain stimulation improves sleep quality in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 63-68.	2.2	59
138	Inferences and power analysis concerning two negative binomial distributions with an application to MRI lesion counts data. <i>Computational Statistics and Data Analysis</i> , 2009, 53, 820-833.	1.2	58
139	Use of eHealth and mHealth technology by persons with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 13-19.	2.0	58
140	Randomized, Controlled Trial of Exercise on Objective and Subjective Sleep in Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 947-958.	3.9	57
141	The relationship between maternal and neonatal anthropometric measurements in term newborns. <i>Obstetrics and Gynecology</i> , 1995, 85, 192-196.	2.4	56
142	Polymorphisms in the NQO1, GSTT and GSTM genes are associated with coronary heart disease and biomarkers of oxidative stress. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2009, 674, 93-100.	1.7	56
143	Cross-sectional analysis of the Myasthenia Gravis Patient Registry: Disability and treatment. <i>Muscle and Nerve</i> , 2019, 60, 707-715.	2.2	56
144	Employment and absenteeism in working-age persons with multiple sclerosis. <i>Journal of Medical Economics</i> , 2017, 20, 493-502.	2.1	55

#	ARTICLE	IF	CITATIONS
145	NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. <i>Journal of Clinical Oncology</i> , 2021, 39, 797-806.	1.6	54
146	Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1304-1305.	3.0	53
147	Video Telehealth Pulmonary Rehabilitation Intervention in Chronic Obstructive Pulmonary Disease Reduces 30-Day Readmissions. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 511-513.	5.6	52
148	Optimizing Patient Selection for Endovascular Treatment in Acute Ischemic Stroke (SELECT): A Prospective, Multicenter Cohort Study of Imaging Selection. <i>Annals of Neurology</i> , 2020, 87, 419-433.	5.3	52
149	Cognition in patients with newly diagnosed brain metastasis: profiles and implications. <i>Journal of Neuro-Oncology</i> , 2014, 120, 179-185.	2.9	51
150	Corrigendum. <i>Neurodegenerative Disease Management</i> , 2016, 6, 178-178.	2.2	50
151	Low birth weight, intrauterine growth retardation, and preterm delivery. <i>American Journal of Obstetrics and Gynecology</i> , 1985, 152, 980-984.	1.3	49
152	Effects of the Sunny Days, Healthy Ways Curriculum on Students in Grades 6 to 8. <i>American Journal of Preventive Medicine</i> , 2006, 30, 13-22.	3.0	49
153	The emotional impact of the COVID-19 pandemic on individuals with progressive multiple sclerosis. <i>Journal of Neurology</i> , 2021, 268, 1598-1607.	3.6	49
154	The patient's perception of a (reliable) change in the Multiple Sclerosis Functional Composite. <i>Multiple Sclerosis Journal</i> , 2004, 10, 55-60.	3.0	48
155	Maternal risk factors and their influence on fetal anthropometric measurements. <i>American Journal of Obstetrics and Gynecology</i> , 1993, 168, 1197-1205.	1.3	47
156	Randomized Trial on the <i>5 a Day, the Rio Grande Way</i> Website, A Web-based Program to Improve Fruit and Vegetable Consumption in Rural Communities. <i>Journal of Health Communication</i> , 2008, 13, 230-249.	2.4	47
157	HYPOTHERMIA AS A RISK FACTOR FOR PEDIATRIC CARDIOTHORACIC SURGICAL SITE INFECTION. <i>Pediatric Infectious Disease Journal</i> , 2001, 20, 459-462.	2.0	47
158	Validation of the NARCOMS Registry: fatigue assessment. <i>Multiple Sclerosis Journal</i> , 2005, 11, 583-584.	3.0	46
159	Compliance with sunscreen advice in a survey of adults engaged in outdoor winter recreation at high-elevation ski areas. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, 63-70.	1.2	46
160	A survey of dietary characteristics in a large population of people with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 22, 12-18.	2.0	46
161	Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. <i>Nature Medicine</i> , 2021, 27, 165-173.	30.7	46
162	Dysregulation of the Adaptive Immune System in Patients With Early-Stage Parkinson Disease. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	46

#	ARTICLE	IF	CITATIONS
163	Correlates of attendance and compliance in the hypertension detection and follow-up program. <i>Contemporary Clinical Trials</i> , 1982, 3, 13-27.	1.9	45
164	A Classification System to Evaluate Weight Maintainers, Gainers, and Losers. <i>Journal of the American Dietetic Association</i> , 1997, 97, 481-488.	1.1	45
165	Low Invasiveness of Pneumococcal Serotype 11A Is Linked to Ficolin-2 Recognition of O-acetylated Capsule Epitopes and Lectin Complement Pathway Activation. <i>Journal of Infectious Diseases</i> , 2014, 210, 1155-1165.	4.0	45
166	Impact of multiple sclerosis relapse: The NARCOMS participant perspective. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 234-240.	2.0	45
167	Scalp EEG spikes predict impending epilepsy in TSC infants: A longitudinal observational study. <i>Epilepsia</i> , 2019, 60, 2428-2436.	5.1	45
168	A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. <i>Neuro-Oncology</i> , 2020, 22, 1527-1535.	1.2	45
169	Self-reported visual dysfunction in multiple sclerosis: results from the 25-Item National Eye Institute Visual Function Questionnaire (VFQ-25). <i>Multiple Sclerosis Journal</i> , 2000, 6, 382-385.	3.0	44
170	Effect of Emailed Messages on Return Use of a Nutrition Education Website and Subsequent Changes in Dietary Behavior. <i>Journal of Medical Internet Research</i> , 2007, 9, e27.	4.3	44
171	Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. <i>Lancet Neurology</i> , The, 2022, 21, 608-619.	10.2	44
172	Enhancing antimelanoma immune responses through apoptosis. <i>Cancer Gene Therapy</i> , 2003, 10, 726-736.	4.6	43
173	Effect of conventional dental restorative treatment on bacteria in saliva. <i>Community Dentistry and Oral Epidemiology</i> , 1992, 20, 138-143.	1.9	41
174	Requiring an amyloid β biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. <i>Alzheimer's and Dementia</i> , 2010, 6, 367-377.	0.8	41
175	Effects of Early Inhaled Nitric Oxide Therapy and Vitamin A Supplementation on the Risk for Bronchopulmonary Dysplasia in Premature Newborns with Respiratory Failure. <i>Journal of Pediatrics</i> , 2014, 164, 744-748.	1.8	41
176	The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1469-1484.	3.0	41
177	Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. <i>Annals of Neurology</i> , 2010, 68, 409-411.	5.3	40
178	Treatment trials in progressive MS—current challenges and future directions. <i>Nature Reviews Neurology</i> , 2013, 9, 496-503.	10.1	40
179	A new way to estimate neurologic disease prevalence in the United States. <i>Neurology</i> , 2019, 92, 469-480.	1.1	40
180	A Study of the Relationship Between Family History of Breast Cancer and Knowledge of Breast Cancer Genetic Testing Prerequisites. <i>Cancer Detection and Prevention</i> , 1999, 23, 22-30.	2.1	40

#	ARTICLE	IF	CITATIONS
181	Validation of the NARCOMS Registry: pain assessment. <i>Multiple Sclerosis Journal</i> , 2005, 11, 338-342.	3.0	39
182	Characteristics of <i>Streptococcus mutans</i> genotypes and dental caries in children. <i>European Journal of Oral Sciences</i> , 2013, 121, 148-155.	1.5	39
183	The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: A systematic review. <i>Multiple Sclerosis Journal</i> , 2015, 21, 332-341.	3.0	39
184	Randomized Trial of Thymectomy in Myasthenia Gravis. <i>New England Journal of Medicine</i> , 2016, 375, 2005-2007.	27.0	39
185	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1031-1044.	3.0	39
186	Transmission of mutans streptococci to infants following short term application of an iodine-NaF solution to mothers' dentition. <i>Community Dentistry and Oral Epidemiology</i> , 1993, 21, 136-142.	1.9	38
187	Predictors of Radiologists' Perceived Risk of Malpractice Lawsuits in Breast Imaging. <i>American Journal of Roentgenology</i> , 2009, 192, 327-333.	2.2	38
188	Substantial adverse association of visual and vascular comorbidities on visual disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2011, 17, 1464-1471.	3.0	38
189	Inflammation, Apoptosis, and Necrosis Induced by Neoadjuvant Fas Ligand Gene Therapy Improves Survival of Dogs With Spontaneous Bone Cancer. <i>Molecular Therapy</i> , 2012, 20, 2234-2243.	8.2	38
190	Implementing clinical trials on an international platform: Challenges and perspectives. <i>Journal of the Neurological Sciences</i> , 2012, 313, 1-6.	0.6	38
191	Constraint-Induced Movement Therapy for the Lower Extremities in Multiple Sclerosis: Case Series With 4-Year Follow-Up. <i>Archives of Physical Medicine and Rehabilitation</i> , 2013, 94, 753-760.	0.9	38
192	The relationship between maternal serum zinc levels during pregnancy and birthweight. <i>Early Human Development</i> , 1991, 25, 75-85.	1.8	37
193	Maternal serum thromboxane B2 reduction versus pregnancy outcome in a low-dose aspirin trial. <i>American Journal of Obstetrics and Gynecology</i> , 1995, 173, 578-584.	1.3	37
194	Optimization of technique factors for a silicon diode array full-field digital mammography system and comparison to screen-film mammography with matched average glandular dose. <i>Medical Physics</i> , 2003, 30, 334-340.	3.0	37
195	Reality Check: Perceived Versus Actual Performance of Community Mammographers. <i>American Journal of Roentgenology</i> , 2006, 187, 42-46.	2.2	37
196	Weight changes associated with unilateral STN DBS and advanced PD. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 709-711.	2.2	37
197	Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFN β -1b study. <i>BMJ Open</i> , 2012, 2, e001972.	1.9	37
198	Increased electroencephalography connectivity precedes epileptic spasm onset in infants with tuberous sclerosis complex. <i>Epilepsia</i> , 2019, 60, 1721-1732.	5.1	37

#	ARTICLE	IF	CITATIONS
199	Evolution of clinical trials in multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2019, 12, 175628641982654.	3.5	37
200	Health Literacy Association With Health Behaviors and Health Care Utilization in Multiple Sclerosis: A Cross-Sectional Study. <i>Interactive Journal of Medical Research</i> , 2014, 3, e3.	1.4	37
201	Current Realities of Delivering Mammography Services in the Community: Do Challenges with Staffing and Scheduling Exist?. <i>Radiology</i> , 2005, 235, 391-395.	7.3	36
202	Increasing Sun Protection in Winter Outdoor Recreation. <i>American Journal of Preventive Medicine</i> , 2008, 34, 502-509.	3.0	36
203	Relapses in multiple sclerosis: Relationship to disability. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 6, 10-20.	2.0	36
204	Which symptoms contribute the most to patients' perception of health in multiple sclerosis?. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2017, 3, 205521731772830.	1.0	36
205	Factors Associated with Discontinuation of Continuous Subcutaneous Insulin Infusion. <i>American Journal of the Medical Sciences</i> , 1988, 295, 23-28.	1.1	35
206	Preliminary Results from the Collaborative Alabama and Scandinavian Study of Successive Small-for-Gestational Age Births: Report from a Symposium in Trondheim 9th June 1988. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 1989, 68, 19-25.	2.8	35
207	CCR2-64I polymorphism and CCR5 ^{Δ32} deletion in patients with Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2004, 225, 79-83.	0.6	35
208	Composite MRI scores improve correlation with EDSS in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1117-1125.	3.0	35
209	Increasing age at disability milestones among MS patients in the MSBase Registry. <i>Journal of the Neurological Sciences</i> , 2012, 318, 94-99.	0.6	35
210	Noninvasive Inhaled Nitric Oxide Does Not Prevent Bronchopulmonary Dysplasia in Premature Newborns. <i>Journal of Pediatrics</i> , 2014, 165, 1104-1108.e1.	1.8	35
211	Fertility restoration of maize <i>CMS</i> altered by a single amino acid substitution within the <i>bHLH</i> transcription factor. <i>Plant Journal</i> , 2020, 101, 101-111.	5.7	35
212	Clinical outcomes and documentation of partial beneficial effects of immunotherapy for multiple sclerosis. <i>Annals of Neurology</i> , 1995, 37, 5-6.	5.3	34
213	Long-Term Survival of African Americans in the Coronary Artery Surgery Study (CASS). <i>Journal of the American College of Cardiology</i> , 1997, 29, 358-364.	2.8	34
214	Effect of <i>APOE</i> genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 349-359.	0.8	34
215	Factors associated with early childhood caries incidence among high caries-risk children. <i>Community Dentistry and Oral Epidemiology</i> , 2015, 43, 366-374.	1.9	34
216	Differences in Alzheimer disease clinical trial outcomes based on age of the participants. <i>Neurology</i> , 2015, 84, 1121-1127.	1.1	34

#	ARTICLE	IF	CITATIONS
217	Drug-drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program. <i>Epilepsy and Behavior</i> , 2019, 98, 201-206.	1.7	34
218	Cognitive functioning following long-term cannabidiol use in adults with treatment-resistant epilepsy. <i>Epilepsy and Behavior</i> , 2019, 97, 105-110.	1.7	34
219	Causes of Death among Commercially Insured Multiple Sclerosis Patients in the United States. <i>PLoS ONE</i> , 2014, 9, e105207.	2.5	34
220	Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial. <i>Journal of Parkinson's Disease</i> , 2022, 12, 557-570.	2.8	34
221	Comorbidity is associated with disease activity in MS. <i>Neurology</i> , 2020, 95, e446-e456.	1.1	33
222	Artificial intelligence extension of the OSCAR criteria. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1528-1542.	3.7	33
223	Elevated levels of midtrimester maternal serum $\hat{\pm}$ -fetoprotein are associated with preterm delivery but not with fetal growth retardation. <i>American Journal of Obstetrics and Gynecology</i> , 1992, 167, 596-601.	1.3	32
224	Low-dose aspirin: Lack of association with an increase in abruptio placentae or perinatal mortality. <i>Obstetrics and Gynecology</i> , 1995, 85, 1055-1058.	2.4	32
225	Clinical and Economic Effects of iNO in Premature Newborns With Respiratory Failure at 1 Year. <i>Pediatrics</i> , 2009, 124, 1333-1343.	2.1	32
226	Real-time quantitative polymerase chain reaction for enumeration of <i>Streptococcus mutans</i> from oral samples. <i>European Journal of Oral Sciences</i> , 2011, 119, 447-454.	1.5	32
227	Pubertal Development in Rett Syndrome Deviates From Typical Females. <i>Pediatric Neurology</i> , 2014, 51, 769-775.	2.1	32
228	The Cancer Information Service Research Consortium: An Emerging Laboratory for Cancer Control Research. <i>Preventive Medicine</i> , 1998, 27, S3-S15.	3.4	31
229	Substantial burden of dizziness in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2013, 2, 21-28.	2.0	31
230	Regional gray matter atrophy in relapsing remitting multiple sclerosis: Baseline analysis of multi-center data. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 124-136.	2.0	31
231	Causes of death among persons with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 484-490.	2.0	31
232	Health insurance affects the use of disease-modifying therapy in multiple sclerosis. <i>Neurology</i> , 2016, 87, 365-374.	1.1	31
233	Gender and quality of life in myasthenia gravis patients from the myasthenia gravis foundation of America registry. <i>Muscle and Nerve</i> , 2018, 58, 90-98.	2.2	31
234	Futility studies: Spending a little to save a lot. <i>Neurology</i> , 2006, 66, 626-627.	1.1	30

#	ARTICLE	IF	CITATIONS
235	Natalizumab reduces relapse clinical severity and improves relapse recovery in MS. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 705-711.	2.0	30
236	Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials. <i>JAMA Network Open</i> , 2018, 1, e184080.	5.9	30
237	Early complement genes are associated with visual system degeneration in multiple sclerosis. <i>Brain</i> , 2019, 142, 2722-2736.	7.6	30
238	Declining Financial Capacity in Mild Cognitive Impairment: A Six-Year Longitudinal Study. <i>Archives of Clinical Neuropsychology</i> , 2019, 34, 152-161.	0.5	30
239	Reducing Immunogenicity of Pegloticase With Concomitant Use of Mycophenolate Mofetil in Patients With Refractory Gout: A Phase II, Randomized, Double-blind, Placebo-controlled Trial. <i>Arthritis and Rheumatology</i> , 2021, 73, 1523-1532.	5.6	30
240	Study protocol: improving cognition in people with progressive multiple sclerosis: a multi-arm, randomized, blinded, sham-controlled trial of cognitive rehabilitation and aerobic exercise (COGEx). <i>BMC Neurology</i> , 2020, 20, 204.	1.8	30
241	Inhaled Nitric Oxide in preterm infants: a systematic review and individual patient data meta-analysis. <i>BMC Pediatrics</i> , 2010, 10, 15.	1.7	29
242	A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2010, 3, 15-28.	3.5	29
243	The association of fatigue and social participation in multiple sclerosis as assessed using two different instruments. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 31, 165-172.	2.0	29
244	Rationale and design of the STEP for MS Trial: Comparative effectiveness of Supervised versus Telerehabilitation Exercise Programs for Multiple Sclerosis. <i>Contemporary Clinical Trials</i> , 2019, 81, 110-122.	1.8	29
245	Hand stereotypies. <i>Neurology</i> , 2019, 92, e2594-e2603.	1.1	29
246	Impact of Refractory Myasthenia Gravis on Health-Related Quality of Life. <i>Journal of Clinical Neuromuscular Disease</i> , 2019, 20, 173-181.	0.7	29
247	Three-year incidence of hypertension in thirteen U.S. communities. <i>Preventive Medicine</i> , 1982, 11, 487-499.	3.4	28
248	Randomized Trial on Sun Safety Education at Ski and Snowboard Schools in Western North America. <i>Pediatric Dermatology</i> , 2007, 24, 222-229.	0.9	28
249	Testing the Long-Term Effects of the Go Sun Smart Worksite Health Communication Campaign: A Group-Randomized Experimental Study. <i>Journal of Communication</i> , 2008, 58, 447-471.	3.7	28
250	The MGTX experience: Challenges in planning and executing an international, multicenter clinical trial. <i>Journal of Neuroimmunology</i> , 2008, 201-202, 80-84.	2.3	28
251	Dysregulation of 14-3-3 proteins in neurodegenerative diseases with Lewy body or Alzheimer pathology. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 466-477.	3.7	28
252	Treatment satisfaction and bothersome bladder, bowel, sexual symptoms in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, 16-21.	2.0	28

#	ARTICLE	IF	CITATIONS
253	Measures of general and abdominal obesity and disability severity in a large population of people with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 976-986.	3.0	28
254	Cervical examination and tocodynamometry at 28 weeks' gestation: Prediction of spontaneous preterm birth. <i>American Journal of Obstetrics and Gynecology</i> , 1995, 172, 666-671.	1.3	27
255	Radiologist Uncertainty and the Interpretation of Screening. <i>Medical Decision Making</i> , 2004, 24, 255-264.	2.4	27
256	Environmental Cues to UV Radiation and Personal Sun Protection in Outdoor Winter Recreation. <i>Archives of Dermatology</i> , 2010, 146, 1241-7.	1.4	27
257	“Seeing” in NARCOMS: a look at vision-related quality of life in the NARCOMS registry. <i>Multiple Sclerosis Journal</i> , 2013, 19, 953-960.	3.0	27
258	Using baseline cognitive severity for enriching Alzheimer's disease clinical trials: How does Mini-Mental State Examination predict rate of change?. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2015, 1, 46-52.	3.7	27
259	Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy. <i>Epilepsy and Behavior</i> , 2021, 117, 107862.	1.7	27
260	Clinical characteristics of progressive relapsing multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2004, 10, 451-454.	3.0	26
261	Care Partners and Multiple Sclerosis. <i>International Journal of MS Care</i> , 2015, 17, 253-260.	1.0	26
262	Epidemiological features of amyotrophic lateral sclerosis in a large clinic-based African American population. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2013, 14, 334-337.	1.7	25
263	Composite end points to assess delay of disability progression by MS treatments. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1494-1501.	3.0	25
264	Intensive Care Unit Readmission during Childhood after Preterm Birth with Respiratory Failure. <i>Journal of Pediatrics</i> , 2014, 164, 749-755.e3.	1.8	25
265	High hypothetical interest in physician-assisted death in multiple sclerosis. <i>Neurology</i> , 2017, 88, 1528-1534.	1.1	25
266	Gender differences in prednisone adverse effects. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2018, 5, e507.	6.0	25
267	High vigabatrin dosage is associated with lower risk of infantile spasms relapse among children with tuberous sclerosis complex. <i>Epilepsy Research</i> , 2018, 148, 1-7.	1.6	25
268	Phase-III, randomized controlled trial of the behavioral intervention for increasing physical activity in multiple sclerosis: Project BIPAMS. <i>Contemporary Clinical Trials</i> , 2018, 71, 154-161.	1.8	25
269	Gender differences in quality of life among patients with myasthenia gravis in China. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 296.	2.4	25
270	How Multiple Sclerosis Symptoms Vary by Age, Sex, and Race/Ethnicity. <i>Neurology: Clinical Practice</i> , 2021, 11, 335-341.	1.6	25

#	ARTICLE	IF	CITATIONS
271	Oral leukoplakia and adolescent smokeless tobacco use. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1991, 72, 35-41.	0.6	24
272	The Prevalence and Predictors of Helmet Use by Skiers and Snowboarders at Ski Areas in Western North America in 2001. <i>Journal of Trauma</i> , 2003, 55, 939-945.	2.3	24
273	Mediation of a middle school skin cancer prevention program.. <i>Health Psychology</i> , 2006, 25, 616-625.	1.6	24
274	Capacity of patients with brain metastases to make treatment decisions. <i>Psycho-Oncology</i> , 2015, 24, 1448-1455.	2.3	24
275	Evaluating risk factors for chronic kidney disease in pediatric patients with sickle cell anemia. <i>Pediatric Nephrology</i> , 2017, 32, 1565-1573.	1.7	24
276	Perspectives on marijuana use and effectiveness. <i>Neurology: Clinical Practice</i> , 2017, 7, 333-343.	1.6	24
277	Reproducibility of cognitive endpoints in clinical trials: lessons from neurofibromatosis type 1. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 2555-2565.	3.7	24
278	Cognitive function and adaptive skills after a one-year trial of cannabidiol (CBD) in a pediatric sample with treatment-resistant epilepsy. <i>Epilepsy and Behavior</i> , 2020, 111, 107299.	1.7	24
279	Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis. <i>Neurology</i> , 2021, 96, e111-e120.	1.1	24
280	The Pediatric Costs of Strategies for Minimizing the Risk of Early-Onset Group B Streptococcal Disease. <i>Obstetrics and Gynecology</i> , 1997, 90, 347-352.	2.4	23
281	Community-Based Mammography Practice: Services, Charges, and Interpretation Methods. <i>American Journal of Roentgenology</i> , 2005, 184, 433-438.	2.2	23
282	Improving the efficiency and effectiveness of pragmatic clinical trials in older adults in the United States. <i>Contemporary Clinical Trials</i> , 2012, 33, 1211-1216.	1.8	23
283	Upper limb impairment is associated with use of assistive devices and unemployment in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 13, 87-92.	2.0	23
284	The effect of unilateral subthalamic nucleus deep brain stimulation on depression in Parkinson's disease. <i>Brain Stimulation</i> , 2017, 10, 651-656.	1.6	23
285	Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b. <i>Multiple Sclerosis Journal</i> , 2019, 25, 837-847.	3.0	23
286	Pilot Study of Neurodevelopmental Impact of Early Epilepsy Surgery in Tuberous Sclerosis Complex. <i>Pediatric Neurology</i> , 2020, 109, 39-46.	2.1	23
287	Central vein sign: A diagnostic biomarker in multiple sclerosis (CAVS-MS) study protocol for a prospective multicenter trial. <i>NeuroImage: Clinical</i> , 2021, 32, 102834.	2.7	23
288	Hydroxychloroquine for Primary Progressive Multiple Sclerosis. <i>Annals of Neurology</i> , 2021, 90, 940-948.	5.3	23

#	ARTICLE	IF	CITATIONS
289	Understanding and Preventing Loss to Follow-up: Experiences From the Spinal Cord Injury Model Systems. <i>Topics in Spinal Cord Injury Rehabilitation</i> , 2018, 24, 97-109.	1.8	23
290	Variability of Interpretive Accuracy Among Diagnostic Mammography Facilities. <i>Journal of the National Cancer Institute</i> , 2009, 101, 814-827.	6.3	22
291	T cell cytokine signatures: Biomarkers in pediatric multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2016, 297, 1-8.	2.3	22
292	Challenging Assumptions About African American Participation in Alzheimer Disease Trials. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 1150-1159.	1.2	22
293	A Framework of Care in Multiple Sclerosis, Part 2. <i>International Journal of MS Care</i> , 2017, 19, 42-56.	1.0	22
294	Smoking Status over Two Years in Patients with Multiple Sclerosis. <i>Neuroepidemiology</i> , 2009, 32, 72-79.	2.3	21
295	Personalized medicine. <i>Neurology: Clinical Practice</i> , 2012, 2, 343-351.	1.6	21
296	Enhancing Industry-Based Dissemination of an Occupational Sun Protection Program with Theory-Based Strategies Employing Personal Contact. <i>American Journal of Health Promotion</i> , 2012, 26, 356-365.	1.7	21
297	Long-Term Cost-Effectiveness Model of Interferon Beta-1b in the Early Treatment of Multiple Sclerosis in the United States. <i>Clinical Therapeutics</i> , 2012, 34, 1966-1976.	2.5	21
298	A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivation. <i>Multiple Sclerosis Journal</i> , 2013, 19, 59-68.	3.0	21
299	Risk tolerance to MS therapies: Survey results from the NARCOMS registry. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 241-249.	2.0	21
300	Prevalence and incidence of early childhood caries among African American children in Alabama. <i>Journal of Public Health Dentistry</i> , 2015, 75, 42-48.	1.2	21
301	Randomized trial of thymectomy in myasthenia gravis. <i>Journal of Thoracic Disease</i> , 2016, 8, E1782-E1783.	1.4	21
302	Neurocognitive Predictors of Declining Financial Capacity in Persons with Mild Cognitive Impairment. <i>Clinical Gerontologist</i> , 2017, 40, 14-23.	2.2	21
303	Phase II Randomized Controlled Trial of Constraint-Induced Movement Therapy in Multiple Sclerosis. Part 1: Effects on Real-World Function. <i>Neurorehabilitation and Neural Repair</i> , 2018, 32, 223-232.	2.9	21
304	Tuberous Sclerosis Complex Genotypes and Developmental Phenotype. <i>Pediatric Neurology</i> , 2019, 96, 58-63.	2.1	21
305	Aggressive multiple sclerosis (2): Treatment. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1045-1063.	3.0	21
306	Promoting Cancer Screening among the First-Degree Relatives of Breast and Colorectal Cancer Patients: The Design of Two Randomized Trials. <i>Preventive Medicine</i> , 1999, 28, 229-242.	3.4	20

#	ARTICLE	IF	CITATIONS
307	Retinal architecture predicts pupillary reflex metrics in MS. <i>Multiple Sclerosis Journal</i> , 2009, 15, 479-486.	3.0	20
308	Trend for decreasing Multiple Sclerosis Severity Scores (MSSS) with increasing calendar year of enrollment into the New York State Multiple Sclerosis Consortium. <i>Multiple Sclerosis Journal</i> , 2011, 17, 725-733.	3.0	20
309	Biomarker development for myasthenia gravis. <i>Annals of the New York Academy of Sciences</i> , 2012, 1275, 101-106.	3.8	20
310	Clinical outcome measures in SPMS trials: An analysis of the IMPACT and ASCEND original trial data sets. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1540-1549.	3.0	20
311	Ageing and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642096901.	3.5	20
312	Disability Outcomes in the N-MOMentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	6.0	20
313	Slow Wave Sleep and EEG Delta Spectral Power are Associated with Cognitive Function in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, 11, 703-714.	2.8	20
314	Who Are the Weight Maintainers?. <i>Obesity</i> , 1995, 3, 249s-259s.	4.0	19
315	Is Bayesian Analysis Ready for Use in Phase III Randomized Clinical Trials?. <i>Stroke</i> , 2005, 36, 1622-1623.	2.0	19
316	Mammographers' Perception of Women's Breast Cancer Risk. <i>Medical Decision Making</i> , 2005, 25, 283-289.	2.4	19
317	Motivating Public School Districts to Adopt Sun Protection Policies. <i>American Journal of Preventive Medicine</i> , 2011, 41, 309-316.	3.0	19
318	EDSS variability before randomization may limit treatment discovery in primary progressive MS. <i>Multiple Sclerosis Journal</i> , 2013, 19, 775-781.	3.0	19
319	Digoxin and 30-day All-cause Hospital Admission in Older Patients with Chronic Diastolic Heart Failure. <i>American Journal of Medicine</i> , 2014, 127, 132-139.	1.5	19
320	Rationale, design, samples, and baseline sun protection in a randomized trial on a skin cancer prevention intervention in resort environments. <i>Contemporary Clinical Trials</i> , 2016, 46, 67-76.	1.8	19
321	Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: An analysis from the EPOC (Evaluate Patient Outcomes) trial. <i>Journal of the Neurological Sciences</i> , 2016, 365, 190-198.	0.6	19
322	Effects of Subthalamic Nucleus Deep Brain Stimulation on Objective Sleep Outcomes in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 183-190.	1.5	19
323	An introduction to Mendelian randomization with applications in neurology. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 24, 72-78.	2.0	19
324	Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis. <i>Neurology</i> , 2021, 97, e1560-e1570.	1.1	19

#	ARTICLE	IF	CITATIONS
325	Sensitivity, specificity and predictive value of saliva thiocyanate among pregnant women. <i>Addictive Behaviors</i> , 1989, 14, 447-452.	3.0	18
326	Characteristics of Severe Hypoglycemia in the Patient With Insulin-Dependent Diabetes. <i>Southern Medical Journal</i> , 1994, 87, 616-620.	0.7	18
327	Smokers with Multiple Sclerosis Are More Likely to Report Comorbid Autoimmune Diseases. <i>Neuroepidemiology</i> , 2011, 36, 85-90.	2.3	18
328	Psychometric evaluation of the myasthenia gravis composite using rasch analysis. <i>Muscle and Nerve</i> , 2012, 45, 820-825.	2.2	18
329	Systematic review of interventional sickle cell trials registered in ClinicalTrials.gov. <i>Clinical Trials</i> , 2015, 12, 575-583.	1.6	18
330	Examining the joint effect of disability, health behaviors, and comorbidity on mortality in MS. <i>Neurology: Clinical Practice</i> , 2016, 6, 397-408.	1.6	18
331	Sun Safe Workplaces. <i>Journal of Occupational and Environmental Medicine</i> , 2018, 60, 990-997.	1.7	18
332	Validation of the SymptoMScreen with performance-based or clinician-assessed outcomes. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 29, 86-93.	2.0	18
333	Cortical Activation Elicited by Subthalamic Deep Brain Stimulation Predicts Postoperative Motor Side Effects. <i>Neuromodulation</i> , 2019, 22, 456-464.	0.8	18
334	The timed 25-foot walk in a large cohort of multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2022, 28, 289-299.	3.0	18
335	Validation of NARCOMS Depression Scale. <i>International Journal of MS Care</i> , 2008, 10, 81-84.	1.0	18
336	Decreased accuracy in interpretation of community-based screening mammography for women with multiple clinical risk factors. <i>Journal of Clinical Epidemiology</i> , 2010, 63, 441-451.	5.0	17
337	Comparative utility of disability progression measures in PPMS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e358.	6.0	17
338	Occupational Therapy Treatment to Improve Upper Extremity Function in Individuals with Early Systemic Sclerosis: A Pilot Study. <i>Arthritis Care and Research</i> , 2018, 70, 1653-1660.	3.4	17
339	Employment in refractory myasthenia gravis: A Myasthenia Gravis Foundation of America Registry analysis. <i>Muscle and Nerve</i> , 2019, 60, 700-706.	2.2	17
340	Minimal manifestation status and prednisone withdrawal in the MGTX trial. <i>Neurology</i> , 2020, 95, e755-e766.	1.1	17
341	COVID-19 in Patients With Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease in North America. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	17
342	DDT contamination of a North Alabama aquatic ecosystem. <i>Environmental Toxicology and Chemistry</i> , 1986, 5, 725-736.	4.3	16

#	ARTICLE	IF	CITATIONS
343	Fetal Growth in Women Using Low-Dose Aspirin for the Prevention of Preeclampsia: Effect of Maternal Size. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 1995, 4, 218-224.	1.5	16
344	VHA Multiple Sclerosis Surveillance Registry and its similarities to other contemporary multiple sclerosis cohorts. <i>Journal of Rehabilitation Research and Development</i> , 2015, 52, 263-272.	1.6	16
345	The promise of futility trials in neurological diseases. <i>Nature Reviews Neurology</i> , 2015, 11, 300-305.	10.1	16
346	Evaluation of baseline corrected QT interval and azithromycin prescriptions in an academic medical center. <i>Journal of Hospital Medicine</i> , 2016, 11, 15-20.	1.4	16
347	A randomized, controlled pilot trial of the Emotional Faces Memory Task: a digital therapeutic for depression. <i>Npj Digital Medicine</i> , 2018, 1, .	10.9	16
348	Telemedicine visits in myasthenia gravis: Expert guidance and the Myasthenia Gravis Core Exam ($MG\text{-}CE$). <i>Muscle and Nerve</i> , 2021, 64, 270-276.	2.2	16
349	AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103356.	2.0	16
350	Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 60, 103735.	2.0	16
351	Neonatal mortality in infants born weighing 501 to 1000 grams. <i>American Journal of Obstetrics and Gynecology</i> , 1985, 151, 608-611.	1.3	15
352	Methodological issues in weight cycling. <i>Annals of Behavioral Medicine</i> , 1996, 18, 280-289.	2.9	15
353	Testing a Theory-Based Health Communication Program: A Replication of <i>Go Sun Smart</i> in Outdoor Winter Recreation. <i>Journal of Health Communication</i> , 2009, 14, 346-365.	2.4	15
354	A Research Model for Investigating the Effects of Artificial Food Colorings on Children With ADHD. <i>Pediatrics</i> , 2011, 127, e1575-e1584.	2.1	15
355	Practice parameters and focusing research: Plasma exchange for myasthenia gravis. <i>Muscle and Nerve</i> , 2011, 43, 625-626.	2.2	15
356	Evolution of MS lesions to black holes under DNA vaccine treatment. <i>Journal of Neurology</i> , 2012, 259, 1375-1382.	3.6	15
357	Patient perspectives on switching disease-modifying therapies in the NARCOMS registry. <i>Patient Preference and Adherence</i> , 2014, 8, 971.	1.8	15
358	Item response theory-based measure of global disability in multiple sclerosis derived from the Performance Scales and related items. <i>BMC Neurology</i> , 2014, 14, 192.	1.8	15
359	Effect of inâ€paining on cortical thickness measurements in multiple sclerosis: A large cohort study. <i>Human Brain Mapping</i> , 2015, 36, 3749-3760.	3.6	15
360	Pooling Morphometric Estimates: A Statistical Equivalence Approach. <i>Journal of Neuroimaging</i> , 2016, 26, 109-115.	2.0	15

#	ARTICLE	IF	CITATIONS
361	Effect of an intervention on observed sun protection by vacationers in a randomized controlled trial at North American resorts. <i>Preventive Medicine</i> , 2017, 99, 29-36.	3.4	15
362	Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 18, 95-102.	2.0	15
363	Medical Rehabilitation: Guidelines to Advance the Field With High-Impact Clinical Trials. <i>Archives of Physical Medicine and Rehabilitation</i> , 2018, 99, 2637-2648.	0.9	15
364	Correlation of Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living scales in the MGTX study. <i>Muscle and Nerve</i> , 2020, 62, 261-266.	2.2	15
365	Assessing Accuracy of Mammography in the Presence of Verification Bias and Intrareader Correlation. <i>Biometrics</i> , 2005, 61, 259-268.	1.4	14
366	Effects of Program Exposure and Engagement With Tailored Prevention Communication on Sun Protection by Young Adolescents. <i>Journal of Health Communication</i> , 2008, 13, 619-636.	2.4	14
367	Chronic Cerebrospinal Vascular Insufficiency Is Not Associated with HLA DRB1*1501 Status in Multiple Sclerosis Patients. <i>PLoS ONE</i> , 2011, 6, e16802.	2.5	14
368	Examining the Impact of Refractory Myasthenia Gravis on Healthcare Resource Utilization in the United States: Analysis of a Myasthenia Gravis Foundation of America Patient Registry Sample. <i>Journal</i>		

#	ARTICLE	IF	CITATIONS
379	Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsingâ€remitting multiple sclerosis. <i>European Journal of Neurology</i> , 2021, 28, 4135-4145.	3.3	13
380	Impact of patient history on residents' evaluation of child sexual abuse. <i>Child Abuse and Neglect</i> , 1995, 19, 943-951.	2.6	12
381	Randomized Trial Evaluating Computer-Based Sun Safety Education for Children in Elementary School. <i>Journal of Cancer Education</i> , 2008, 23, 74-79.	1.3	12
382	Sustainability of the Dissemination of an Occupational Sun Protection Program in a Randomized Trial. <i>Health Education and Behavior</i> , 2012, 39, 498-502.	2.5	12
383	Dissemination of Go Sun Smart in Outdoor Recreation: Effect of Program Exposure on Sun Protection of Guests at High-Altitude Ski Areas. <i>Journal of Health Communication</i> , 2014, 19, 999-1016.	2.4	12
384	Continuous Electroencephalography (cEEG) Monitoring and Outcomes of Critically Ill Patients. <i>Medical Science Monitor</i> , 2017, 23, 649-658.	1.1	12
385	Higher satisfaction and adherence with glatiramer acetate 40â€mg/mL TIW vs 20â€mg/mL QD in RRMS. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 33, 13-21.	2.0	12
386	Evaluation of a web-based fall prevention program among people with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 31, 151-156.	2.0	12
387	Early Cardiac and Cerebral Hemodynamics with Umbilical Cord Milking Compared with Delayed Cord Clamping in Infants Born Preterm. <i>Journal of Pediatrics</i> , 2020, 223, 51-56.e1.	1.8	12
388	Is the Symbol Digit Modalities Test a useful outcome in secondary progressive multiple sclerosis?. <i>European Journal of Neurology</i> , 2021, 28, 2115-2120.	3.3	12
389	Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum. <i>Neurology</i> , 2021, 97, e1334-e1342.	1.1	12
390	Effects of walking exercise training on learning and memory and hippocampal neuroimaging outcomes in MS: A targeted, pilot randomized controlled trial. <i>Contemporary Clinical Trials</i> , 2021, 110, 106563.	1.8	12
391	Association Between Early Childhood Caries and Colonization with Genotypes From Mothers. <i>Pediatric Dentistry (discontinued)</i> , 2017, 39, 130-135.	0.4	12
392	NARCOMS and Other Registries in Multiple Sclerosis. <i>International Journal of MS Care</i> , 2021, 23, 276-284.	1.0	12
393	Modeling lesion counts in multiple sclerosis when patients have been selected for baseline activity. <i>Multiple Sclerosis Journal</i> , 2010, 16, 926-934.	3.0	11
394	Optimal design and analysis of phase I/II clinical trials in multiple sclerosis with gadolinium-enhanced lesions as the endpoint. <i>Multiple Sclerosis Journal</i> , 2010, 16, 840-847.	3.0	11
395	Defining standard enzymatic dissociation methods for individual brains and spinal cords in EAE. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e437.	6.0	11
396	A contemporary profile of primary progressive multiple sclerosis participants from the NARCOMS Registry. <i>Multiple Sclerosis Journal</i> , 2018, 24, 951-962.	3.0	11

#	ARTICLE	IF	CITATIONS
397	Learning from the past: reflections on recently completed myasthenia gravis trials. <i>Annals of the New York Academy of Sciences</i> , 2018, 1412, 5-13.	3.8	11
398	Results of a Randomized Trial on an Intervention Promoting Adoption of Occupational Sun Protection Policies. <i>American Journal of Health Promotion</i> , 2018, 32, 1042-1053.	1.7	11
399	Multiple sclerosis: clinical trial design 2019. <i>Current Opinion in Neurology</i> , 2019, 32, 358-364.	3.6	11
400	Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD. <i>Multiple Sclerosis Journal</i> , 2021, 27, 2052-2061.	3.0	11
401	Disease-modifying therapy prescription patterns in people with multiple sclerosis by age. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110064.	3.5	11
402	Statistical issues in neutralizing antibodies. <i>Neurology</i> , 2003, 61, S38-9.	1.1	11
403	The Effect of Degree of Refractive Error on Hydrogel Contact Lens-Induced Complications and Patient Self-Management Behaviors. <i>Optometry and Vision Science</i> , 2001, 78, 652-656.	1.2	10
404	Comparison of weight changes following unilateral and staged bilateral STN DBS for advanced PD. <i>Brain and Behavior</i> , 2011, 1, 12-18.	2.2	10
405	Biomarker Positive and Negative Subjects in the ADNI Cohort: Clinical Characterization. <i>Current Alzheimer Research</i> , 2012, 9, 1135-1141.	1.4	10
406	Treatment With Interferon Beta for Multiple Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 1627.	7.4	10
407	The magnetic resonance imaging "rule of five": predicting the occurrence of relapse. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1760-1764.	3.0	10
408	Potentially Modifiable Factors Associated With Physical Activity in Individuals With Multiple Sclerosis. <i>Research in Nursing and Health</i> , 2017, 40, 143-152.	1.6	10
409	A Randomized Trial of an Advanced Sun Safety Intervention for Vacationers at 41 North American Resorts. <i>Journal of Health Communication</i> , 2017, 22, 951-963.	2.4	10
410	Pseudobulbar affect. <i>Neurology: Clinical Practice</i> , 2018, 8, 472-481.	1.6	10
411	Protocol for a systematically-developed, phase I/II, single-blind randomized controlled trial of treadmill walking exercise training effects on cognition and brain function in persons with multiple sclerosis. <i>Contemporary Clinical Trials</i> , 2019, 87, 105878.	1.8	10
412	Clinical trials in multiple sclerosis: potential future trial designs. <i>Therapeutic Advances in Neurological Disorders</i> , 2019, 12, 175628641984709.	3.5	10
413	Video Telehealth Pulmonary Rehabilitation for Chronic Obstructive Pulmonary Disease Is Associated with Clinical Improvement Similar to Center-based Pulmonary Rehabilitation. <i>Annals of the American Thoracic Society</i> , 2022, 19, 331-333.	3.2	10
414	Cardiorespiratory fitness and free-living physical activity are not associated with cognition in persons with progressive multiple sclerosis: Baseline analyses from the CogEx study. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1091-1100.	3.0	10

#	ARTICLE	IF	CITATIONS
415	Usefulness of various maternal skinfold measurements for predicting newborn birth weight. <i>Journal of the American Dietetic Association</i> , 1992, 92, 1393-1394.	1.1	10
416	Muscle magnetic resonance imaging in myotonic dystrophy type 1 (DM1): Refining muscle involvement and implications for clinical trials. <i>European Journal of Neurology</i> , 2022, 29, 843-854.	3.3	10
417	The emerging postural instability phenotype in idiopathic Parkinson disease. <i>Npj Parkinson's Disease</i> , 2022, 8, 28.	5.3	10
418	The agenda of the global patient reported outcomes for multiple sclerosis (PROMS) initiative: Progresses and open questions. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 61, 103757.	2.0	10
419	Distinct populations of label-retaining cells in the adult kidney are defined temporally and exhibit divergent regional distributions. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 307, F1274-F1282.	2.7	9
420	Clinical trial design for progressive MS trials. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1642-1648.	3.0	9
421	Factors associated with excessive sitting time in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 21, 71-77.	2.0	9
422	Impacting development in infants with tuberous sclerosis complex: Multidisciplinary research collaboration.. <i>American Psychologist</i> , 2019, 74, 356-367.	4.2	9
423	A Randomized Internet-Based Pilot Feasibility and Planning Study of Cherry Extract and Diet Modification in Gout. <i>Journal of Clinical Rheumatology</i> , 2020, 26, 147-156.	0.9	9
424	Using practice effects for targeted trials or sub-group analysis in Alzheimer's disease: How practice effects predict change over time. <i>PLoS ONE</i> , 2020, 15, e0228064.	2.5	9
425	Visual spatial learning outcomes for clinical trials in neurofibromatosis type 1. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 245-249.	3.7	9
426	Longitudinal impact of cannabidiol on EEG measures in subjects with treatment-resistant epilepsy. <i>Epilepsy and Behavior</i> , 2021, 122, 108190.	1.7	9
427	Physical activity and self-reported sleep quality in adults with multiple sclerosis. <i>Disability and Health Journal</i> , 2021, 14, 101133.	2.8	9
428	A Framework of Care in Multiple Sclerosis, Part 1. <i>International Journal of MS Care</i> , 2016, 18, 314-323.	1.0	9
429	Factors predicting efficacy of phentolamine-papaverine intracorporeal injection for treatment of erectile dysfunction in diabetic male. <i>Urology</i> , 1992, 40, 36-40.	1.0	8
430	Go Sun Smart. <i>Communication Education</i> , 2008, 57, 423-433.	1.1	8
431	Sample Size in Obesity Trials: Patient Perspective Versus Current Practice. <i>Medical Decision Making</i> , 2010, 30, 68-75.	2.4	8
432	Adopting an evidence-based lifestyle physical activity program: dissemination study design and methods. <i>Translational Behavioral Medicine</i> , 2012, 2, 199-208.	2.4	8

#	ARTICLE	IF	CITATIONS
433	Effect of Nicotine Replacement Therapy on Quitting by Young Adults in a Trial Comparing Cessation Services. <i>Journal of Public Health Management and Practice</i> , 2014, 20, E7-E15.	1.4	8
434	Clinical trials in multiple sclerosis. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2014, 122, 445-453.	1.8	8
435	Mutans streptococci enumeration and genotype selection using different bacitracin-containing media. <i>Journal of Microbiological Methods</i> , 2014, 103, 53-57.	1.6	8
436	Sustained use of an occupational sun safety program in a recreation industry: follow-up to a randomized trial on dissemination strategies. <i>Translational Behavioral Medicine</i> , 2015, 5, 361-371.	2.4	8
437	Effect of switching from intramuscular interferon β -1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS. <i>Contemporary Clinical Trials</i> , 2015, 41, 69-74.	1.8	8
438	Post Hoc Analyses of ApoE Genotype-Defined Subgroups in Clinical Trials. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 1205-1215.	2.6	8
439	Rationale and design of a single-blind, randomised controlled trial of exercise training for managing learning and memory impairment in persons with multiple sclerosis. <i>BMJ Open</i> , 2018, 8, e023231.	1.9	8
440	Gender identity and sexual orientation affect health care satisfaction, but not utilization, in persons with Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101440.	2.0	8
441	Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury. <i>New England Journal of Medicine</i> , 2020, 383, 1796-1798.	27.0	8
442	Genomic Copy Number Variants: Evidence for Association with Antibody Response to Anthrax Vaccine Adsorbed. <i>PLoS ONE</i> , 2013, 8, e64813.	2.5	8
443	Interferon- β for multiple sclerosis: Long-term benefits?. <i>Annals of Neurology</i> , 2007, 61, 283-285.	5.3	7
444	Bayesian interim analysis in clinical trials. <i>Contemporary Clinical Trials</i> , 2008, 29, 751-755.	1.8	7
445	Statistical cures and other fallacies. <i>Multiple Sclerosis Journal</i> , 2012, 18, 387-390.	3.0	7
446	The Sustainability of an Occupational Skin Cancer Prevention Program. <i>Journal of Occupational and Environmental Medicine</i> , 2015, 57, 1207-1213.	1.7	7
447	Baseline EDSS proportions in MS clinical trials affect the overall outcome and power: A cautionary note. <i>Multiple Sclerosis Journal</i> , 2017, 23, 982-987.	3.0	7
448	Clinical trials in multiple sclerosis: milestones. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628641878549.	3.5	7
449	Histopathology of thymectomy specimens from the MGTX-trial: Entropy analysis as strategy to quantify spatial heterogeneity of lymphoid follicle and fat distribution. <i>PLoS ONE</i> , 2018, 13, e0197435.	2.5	7
450	CYP3A5 genotype affects time to therapeutic tacrolimus level in pediatric kidney transplant recipients. <i>Pediatric Transplantation</i> , 2019, 23, e13494.	1.0	7

#	ARTICLE	IF	CITATIONS
451	Functional gastrointestinal disorders negatively affect health-related quality of life in MS. <i>Neurology: Clinical Practice</i> , 2019, 9, 381-390.	1.6	7
452	Implementation of Occupational Sun Safety at a 2-Year Follow-Up in a Randomized Trial: Comparison of Sun Safe Workplaces Policy Intervention to Attention Control. <i>American Journal of Health Promotion</i> , 2019, 33, 683-697.	1.7	7
453	Longitudinal Analysis of Disease Burden in Refractory and Nonrefractory Generalized Myasthenia Gravis in the United States. <i>Journal of Clinical Neuromuscular Disease</i> , 2020, 22, 11-21.	0.7	7
454	A longitudinal study of symptom botheration in Multiple Sclerosis.. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102585.	2.0	7
455	Feasibility of improving dietary quality using a telehealth lifestyle intervention for adults with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102504.	2.0	7
456	A comparison of clinical outcomes in PPMS in the INFORMS original trial data set. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1864-1874.	3.0	7
457	Uptake and Attitudes About Immunizations in People With Multiple Sclerosis. <i>Neurology: Clinical Practice</i> , 2021, 11, 327-334.	1.6	7
458	A novel Mendelian randomization method with binary risk factor and outcome. <i>Genetic Epidemiology</i> , 2021, 45, 549-560.	1.3	7
459	MHC-dependent desensitization of intrinsic anti-self reactivity. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 171-185.	4.2	6
460	MRI lesions: a surrogate for relapses in multiple sclerosis?. <i>Lancet Neurology</i> , The, 2013, 12, 628-630.	10.2	6
461	Recruitment of participants to a multiple sclerosis trial: The CombiRx experience. <i>Clinical Trials</i> , 2014, 11, 159-166.	1.6	6
462	Improvement of multiple sclerosis-associated tremor as a treatment effect of natalizumab. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 505-512.	2.0	6
463	Two-group time-to-event continual reassessment method using likelihood estimation. <i>Contemporary Clinical Trials</i> , 2015, 45, 340-345.	1.8	6
464	Pedestrian safety in patients with Parkinson's disease: A caseâ€control study. <i>Movement Disorders</i> , 2017, 32, 1748-1755.	3.9	6
465	Neurofibromatosis Clinical Trial Consortium. <i>Journal of Child Neurology</i> , 2018, 33, 82-91.	1.4	6
466	EFFECT size or statistical significance, where to put your money. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 38, 101490.	2.0	6
467	Treatment response score to glatiramer acetate or interferon beta-1a. <i>Neurology</i> , 2020, 96, 10.1212/WNL.0000000000010991.	1.1	6
468	Satisfaction and adherence with glatiramer acetate 40mg/mL TIW in RRMS after 12 months, and the effect of switching from 20mg/mL QD. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 40, 101957.	2.0	6

#	ARTICLE	IF	CITATIONS
469	Acute flaccid myelitis: long-term outcomes recorded in the CAPTURE study compared with paediatric transverse myelitis. <i>BMJ Neurology Open</i> , 2021, 3, e000127.	1.6	6
470	Distributed data analysis in a multicenter study: The CARDIA study. <i>Contemporary Clinical Trials</i> , 1992, 13, 80-90.	1.9	5
471	Sample size estimates for determining treatment effects in high-risk patients with early relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2003, 9, 289-292.	3.0	5
472	Estimating power with effect size versus slop differences: Both means and variance matter. , 2011, 7, 247-249.		5
473	A retrospective review of lithium usage in veterans with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2013, 2, 327-333.	2.0	5
474	National Variation of Technical Factors in Computed Tomography of the Head. <i>Journal of Computer Assisted Tomography</i> , 2013, 37, 486-492.	0.9	5
475	Publication outcomes of abstracts from the American Society of Hematology Annual Meeting. <i>American Journal of Hematology</i> , 2017, 92, E81-E83.	4.1	5
476	Laquinimod has no effects on brain volume or cellular CNS composition in the F1 3xTg-AD/C3H mouse model of Alzheimer's disease. <i>Journal of Neuroimmunology</i> , 2017, 309, 100-110.	2.3	5
477	Assessing the feasibility of the Effectiveness of Discontinuing Bisphosphonates trial: a pilot study. <i>Osteoporosis International</i> , 2017, 28, 2495-2503.	3.1	5
478	Short-term disability progression in two multiethnic multiple sclerosis centers in the treatment era. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628641879361.	3.5	5
479	Developing a crosswalk between the RAND-12 and the health utilities index for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1102-1110.	3.0	5
480	Effect size "one size doesn't fit all. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102587.	2.0	5
481	New applications for independent activities of daily living in measuring disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 97-106.	3.0	5
482	A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimod. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110211.	3.5	5
483	The Importance and Opportunity for Healthy Aging Through Lifestyle, Behavior Medicine Among Older Adults With Multiple Sclerosis: the Case Based on Physical Activity. <i>Current Treatment Options in Neurology</i> , 2021, 23, 1.	1.8	5
484	MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 561-572.	3.0	5
485	Development of an exosomal gene signature to detect residual disease in dogs with osteosarcoma using a novel xenograft platform and machine learning. <i>Laboratory Investigation</i> , 2021, 101, 1585-1596.	3.7	5
486	An Intervention for Changing Sedentary Behavior Among African Americans With Multiple Sclerosis: Protocol. <i>JMIR Research Protocols</i> , 2019, 8, e12973.	1.0	5

#	ARTICLE	IF	CITATIONS
487	Analysis of Diagnoses Associated with Multiple Sclerosis-Related In-Hospital Mortality Using the Premier Hospital Database. <i>International Journal of MS Care</i> , 2016, 18, 154-161.	1.0	5
488	The impact of the COVID-19 pandemic on an international rehabilitation study in MS: the CogEx experience. <i>Journal of Neurology</i> , 2022, 269, 1758-1763.	3.6	5
489	Diet Quality Assessment in Wheelchair Users with Multiple Sclerosis. <i>Nutrients</i> , 2021, 13, 4352.	4.1	5
490	The relationship between processing speed and verbal and non-verbal new learning and memory in progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, , 135245852210881.	3.0	5
491	One-year follow-up of disease burden and medication changes in patients with myasthenia gravis: From the ^{MG} Patient Registry. <i>Muscle and Nerve</i> , 2022, 66, 411-420.	2.2	5
492	A study of the cost of tuberculosis contact investigation related to non-tuberculous Mycobacterial isolation in Jefferson County, Alabama. <i>Public Health</i> , 1987, 101, 297-304.	2.9	4
493	The MS Cooperative Research (MS-CORE) group: an alternate approach to fostering multicenter studies. <i>Multiple Sclerosis Journal</i> , 2004, 10, 332-335.	3.0	4
494	Temporal characteristics of cold pain perception. <i>Neuroscience Letters</i> , 2010, 480, 12-15.	2.1	4
495	Bayesian sample size determination under hypothesis tests. <i>Contemporary Clinical Trials</i> , 2011, 32, 393-398.	1.8	4
496	Effect of sample size re-estimation in adaptive clinical trials for Alzheimer's disease and mild cognitive impairment. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2015, 1, 63-71.	3.7	4
497	Multiple sclerosis drugs: how much bang for the buck?. <i>Lancet Neurology</i> , The, 2015, 14, 460-461.	10.2	4
498	071...Natalizumab extended interval dosing (EID) is associated with a significant reduction in progressive multifocal leukoencephalopathy (PML) risk compared with standard interval dosing (SID) in the touch[®] prescribing program. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A29.2-A29.	1.9	4
499	LB 1: Premature Infants Receiving Cord Milking or Delayed Cord Clamping: A Randomized Controlled Non-inferiority Trial. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 220, S682.	1.3	4
500	Feasibility of "Sit Less, Move More": An intervention for reducing sedentary behavior Among African Americans with MS. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020, 6, 205521732093234.	1.0	4
501	Education Research: Multiple sclerosis and neuroimmunology fellowship training status in the United States. <i>Neurology</i> , 2020, 94, 495-500.	1.1	4
502	Comparative responsiveness of the health utilities index and the RAND-12 for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1781-1789.	3.0	4
503	UAB-UCSD O'Brien Center for Acute Kidney Injury Research. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 320, F870-F882.	2.7	4
504	Smoking, obesity, and disability worsening in PPMS: an analysis of the INFORMS original trial dataset. <i>Journal of Neurology</i> , 2022, 269, 1663-1669.	3.6	4

#	ARTICLE	IF	CITATIONS
505	Arteriovenous Fistula Nonmaturation: What's the Immune System Got to Do with It?. <i>Kidney360</i> , 2021, 2, 1743-1751.	2.1	4
506	Proportional constrained longitudinal data analysis models for clinical trials in sporadic Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2022, 8, e12286.	3.7	4
507	The timed 25-foot walk is a more sensitive outcome measure than the EDSS for PPMS trials: an analysis of the PROMISE clinical trial dataset. <i>Journal of Neurology</i> , 2022, 269, 5319-5327.	3.6	4
508	Perceptions of physical activity guidelines among wheelchair users with multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2022, 8, 205521732210975.	1.0	4
509	Attitudes toward coronavirus disease 2019 vaccination in people with multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2022, 8, 205521732211020.	1.0	4
510	Thalamic atrophy moderates associations among aerobic fitness, cognitive processing speed, and walking endurance in persons with multiple sclerosis. <i>Journal of Neurology</i> , 0, , .	3.6	4
511	Comparison of Hypertension Prevalence and Control in 5,237 Rural and Urban Alabama Residents. <i>Southern Medical Journal</i> , 1987, 80, 1220-1223.	0.7	3
512	Relapses in multiple sclerosis. <i>Neurology</i> , 2009, 73, 1612-1613.	1.1	3
513	Got milk?. <i>Annals of Neurology</i> , 2011, 70, 3-4.	5.3	3
514	Does Natalizumab Therapy Benefit Patients With Multiple Sclerosis?. <i>JAMA Neurology</i> , 2014, 71, 945.	9.0	3
515	Bifactor structure of clinical disability in relapsing multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 176-185.	2.0	3
516	Statistical Considerations for an Adaptive Design for a Serious Rare Disease. <i>Therapeutic Innovation and Regulatory Science</i> , 2016, 50, 375-384.	1.6	3
517	The Virtual Short Physical Performance Battery: Psychometric Properties and Validation in Older Adults With Multiple Sclerosis. <i>Journal of Applied Gerontology</i> , 2019, 38, 1492-1505.	2.0	3
518	Progression of Alzheimer's Disease by Self-Reported Cancer History in the Alzheimer's Disease Neuroimaging Initiative. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 691-701.	2.6	3
519	CSF plasmablasts differentiate MS from other neurologic disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 48, 102719.	2.0	3
520	Characterizing Long-term Disability Progression and Employment in NARCOMS Registry Participants with Multiple Sclerosis Taking Dimethyl Fumarate. <i>International Journal of MS Care</i> , 2021, 23, 239-244.	1.0	3
521	Demographic, clinical, and symptomatic correlates of subjective sleep quality in adults with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 55, 103204.	2.0	3
522	Accuracy and Repeatability of Internet-ordered Spectacle Lenses. <i>Optometry and Vision Science</i> , 2021, 98, 1340-1347.	1.2	3

#	ARTICLE	IF	CITATIONS
523	NFB-09. ENROLLMENT AND CLINICAL CHARACTERISTICS OF NEWLY DIAGNOSED, NEUROFIBROMATOSIS TYPE 1 ASSOCIATED OPTIC PATHWAY GLIOMA (NF1-OPG): PRELIMINARY RESULTS FROM AN INTERNATIONAL MULTI-CENTER NATURAL HISTORY STUDY. <i>Neuro-Oncology</i> , 2020, 22, iii419-iii419.	1.2	3
524	The Non-Inferiority Complex: What Do Non-Inferiority Trials Tell Us?. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 674-676.	6.1	3
525	COVID-19 in the pregnant or postpartum MS patient: Symptoms and outcomes. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 65, 104028.	2.0	3
526	A new device for collecting cord blood. <i>Obstetrics and Gynecology</i> , 1995, 86, 850-852.	2.4	2
527	Evidence of treatment benefit: is seeing believing or obfuscation by statistics?. <i>Multiple Sclerosis Journal</i> , 2009, 15, 1251-1252.	3.0	2
528	Continued Benefits of a Technical Assistance Web Site to Local Tobacco Control Coalitions During a State Budget Shortfall. <i>Journal of Public Health Management and Practice</i> , 2011, 17, E10-E19.	1.4	2
529	Supporting Tobacco Control. <i>Health Promotion Practice</i> , 2011, 12, 186S-194S.	1.6	2
530	The Problem of Spurious Correlations Between Pairs of Brain Metabolite Values Measured in the Same Voxel With Magnetic Resonance Spectroscopy—Reply. <i>JAMA Psychiatry</i> , 2014, 71, 339.	11.0	2
531	Declines in the diagnosis of primary progressive MS: A critical change in phenotype or critical measurement error?. <i>Multiple Sclerosis Journal</i> , 2016, 22, 983-985.	3.0	2
532	Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree. <i>BMC Neurology</i> , 2016, 16, 176.	1.8	2
533	3: Azithromycin-based extended spectrum antibiotic prophylaxis for non-elective cesarean delivery: a pragmatic multicenter placebo-controlled double-blind rct. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 214, S3.	1.3	2
534	Long-term registries. <i>Neurology: Clinical Practice</i> , 2016, 6, 97-99.	1.6	2
535	Relationship between symptom change, relapse activity and disability progression in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2016, 362, 121-126.	0.6	2
536	To catch a crook, you might try statistics. <i>Nature Reviews Neurology</i> , 2017, 13, 9-10.	10.1	2
537	Patient-Centered Outcomes and Key Study Procedure Finalization in the Pilot Feasibility Gout Randomized Trial. <i>Journal of Clinical Rheumatology</i> , 2020, 26, 181-191.	0.9	2
538	Design and baseline data of a randomized trial comparing two methods for scaling-up an occupational sun protection intervention. <i>Contemporary Clinical Trials</i> , 2020, 97, 106147.	1.8	2
539	An enrichment strategy for clinical trials in SPMS. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1884-1893.	3.0	2
540	Preliminary report of a multicenter, phase 2 study of bevacizumab in children and adults with neurofibromatosis 2 and progressive vestibular schwannomas: An NF Clinical Trials Consortium study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2056-2056.	1.6	2

#	ARTICLE	IF	CITATIONS
541	Multiple Sclerosis Diagnostic Criteria. <i>Neurology</i> , 2022, 98, 12-13.	1.1	2
542	The Effect of Body Mass Index on Brain Volume and Cognitive Function in Relapsing–Remitting Multiple sclerosis: A CombiRx Secondary Analysis. <i>Journal of Central Nervous System Disease</i> , 2021, 13, 117957352110421.	1.9	2
543	Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS. <i>Multiple Sclerosis Journal</i> , 2022, , 135245852210845.	3.0	2
544	OR.2. Epitope-Specific Therapy in Rheumatoid Arthritis, Phase 2 Clinical and Immunological Results. <i>Clinical Immunology</i> , 2006, 119, S4.	3.2	1
545	Rules of Evidence for Clinical Trials. <i>Annals of the New York Academy of Sciences</i> , 2008, 1132, 233-237.	3.8	1
546	Novel designs for clinical trials in multiple sclerosis: another excursion to Sirenum scopuli?. <i>Therapy: Open Access in Clinical Medicine</i> , 2008, 5, 613-622.	0.2	1
547	Erratum to “The MGTX experience: Challenges in planning and executing an international, multicenter clinical trial–[J. <i>Neuroimmunol.</i> 201–202(2008)80–84]. <i>Journal of Neuroimmunology</i> , 2009, 217, 103.	2.3	1
548	A Bayesian Method of Estimating Kappa Coefficient with Application to a Rheumatoid Arthritis Study. <i>Communications in Statistics - Theory and Methods</i> , 2009, 38, 3432-3444.	1.0	1
549	Response to the Letter “Efficiency loss due to varying cluster sizes in cluster randomized trials and how to compensate for it: comment on You et al. (2011)– by van Breukelen and Candel. <i>Clinical Trials</i> , 2012, 9, 126-127.	1.6	1
550	Reply. <i>Muscle and Nerve</i> , 2013, 47, 145-146.	2.2	1
551	Sustained High Level of Healthcare Worker Adherence With Hand Hygiene Practice Recommendations Using the Patient-as-Observer Approach in the Ambulatory Setting. <i>Infection Control and Hospital Epidemiology</i> , 2016, 37, 1496-1498.	1.8	1
552	Sales to apparently alcohol-intoxicated customers and online responsible vendor training in recreational cannabis stores in a randomized trial. <i>International Journal of Drug Policy</i> , 2020, 83, 102860.	3.3	1
553	Rett syndrome: Novel correlations linking >96% genotype, disease severity, and seizures. <i>Translational Science of Rare Diseases</i> , 2021, 5, 131-141.	1.5	1
554	Chronobiology of Hypertension in Sickle Cell Disease. <i>Blood</i> , 2014, 124, 4094-4094.	1.4	1
555	Mendelian randomization in the multivariate general linear model framework. <i>Genetic Epidemiology</i> , 2022, 46, 17-31.	1.3	1
556	Cerebellar pathology and disability worsening in relapsing–remitting multiple sclerosis: a retrospective analysis from the CombiRx trial. <i>European Journal of Neurology</i> , 2021, 29, 515.	3.3	1
557	If Thymectomy Reduces the Risk of Progression of Ocular to Generalized Myasthenia Gravis, Who Should Receive it?. <i>Neurotherapeutics</i> , 2021, 18, 2419-2420.	4.4	1
558	Abstract CT233: Treatment of neurofibromatosis type 1 (NF1)-related plexiform neurofibromas (PN) with cabozantinib (XL184): A Neurofibromatosis Clinical Trials Consortium Phase II trial. , 2019, , .		1

#	ARTICLE	IF	CITATIONS
559	Do physical activity, cardiorespiratory fitness, and subcortical brain structures explain reduced walking performance in older adults with multiple sclerosis?. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 60, 103702.	2.0	1
560	A Survey of Cannabis Use in a Large US-Based Cohort of People with Multiple Sclerosis. <i>International Journal of MS Care</i> , 2021, 23, 245-252.	1.0	1
561	Impact of clinical outcomes and imaging measures on health-related quality of life in secondary progressive MS. <i>Multiple Sclerosis Journal</i> , 2021, , 135245852110636.	3.0	1
562	Early first-line treatment response and subsequent disability worsening in relapsing-remitting multiple sclerosis. <i>European Journal of Neurology</i> , 2022, 29, 1106-1116.	3.3	1
563	Development and validation of a VA risk function to predict mortality. <i>Contemporary Clinical Trials</i> , 1981, 2, 89.	1.9	0
564	Response from Findley, et al. <i>American Journal of Public Health</i> , 1984, 74, 392-392.	2.7	0
565	Cost-Effectiveness of Prevention, Intervention, and Therapeutic Strategies in Coronary Artery Disease. <i>Drug Information Journal</i> , 1988, 22, 425-448.	0.5	0
566	Clinical outcomes assessment in multiple sclerosis: Part II. <i>Multiple Sclerosis Journal</i> , 1996, 2, 247-248.	3.0	0
567	Kinetics of Immune Tolerization in a Clinical Trial on Epitope-specific Therapy in Rheumatoid Arthritis (RA). <i>Clinical Immunology</i> , 2007, 123, S96-S97.	3.2	0
568	Responsiveness and predictive values in PPMS. <i>Neurology</i> , 2008, 70, 1061-1062.	1.1	0
569	Factors That Predict Adoption and Implementation of an Evidence-based Physical Activity Program. <i>Medicine and Science in Sports and Exercise</i> , 2011, 43, 694.	0.4	0
570	Author response: High hypothetical interest in physician-assisted death in multiple sclerosis. <i>Neurology</i> , 2017, 89, 1429-1430.	1.1	0
571	Clinical Trial Design for Myasthenia Gravis. , 2018, , 335-344.		0
572	Reply to: Exercise for "Sleep Rehabilitation" in Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1286-1286.	3.9	0
573	Anticholinergic burden among participants in Alzheimer's™s clinical trials. <i>Alzheimer's and Dementia</i> , 2020, 16, e044362.	0.8	0
574	Comorbidity burden in Alzheimer's™s disease clinical trials. <i>Alzheimer's and Dementia</i> , 2020, 16, e046180.	0.8	0
575	Association of Umbilical Cord Milking vs Delayed Umbilical Cord Clamping With Death or Severe Intraventricular Hemorrhage Among Preterm Infants. <i>Obstetrical and Gynecological Survey</i> , 2020, 75, 212-214.	0.4	0
576	Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients With Parkinson's Disease and a <i>GBA</i> Mutation: Results From Part 1 of the Randomised, Double-Blinded, Placebo-Controlled MOVES-PD Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
577	Randomized Trial Testing an Online Responsible Vendor Training in Recreational Marijuana Stores in the United States. <i>Journal of Studies on Alcohol and Drugs</i> , 2021, 82, 204-213.	1.0	0
578	521 Prevalence and Impact of Restless Legs in Patients with Myasthenia Gravis. <i>Sleep</i> , 2021, 44, A205-A206.	1.1	0
579	Abstract 1747: Oncolytic Vesicular Stomatitis Virus expressing a species relevant interferon-beta is safe and provides a survival benefit when added as neoadjuvant to the standard of care for dogs with naturally occurring bone cancer. , 2021, , .		0
580	Abstract 671: Development of an exosomal biomarker signature to detect minimal residual disease in dogs with osteosarcoma using a novel xenograft platform and machine learning. , 2021, , .		0
581	Cannabis Use for Symptom Management Among People with Multiple Sclerosis (PwMS): A 2020 NARCOMS Survey. <i>Archives of Physical Medicine and Rehabilitation</i> , 2021, 102, e23-e24.	0.9	0
582	Nutrition Monitoring and Research Studies. , 2001, , .		0
583	Nutrition Monitoring and Research Studies. , 2007, , 471-480.		0
584	Association, Cause, and Correlation. , 2008, , 279-294.		0
585	Women and Neurological Disability: End-of-Life Care and Mortality in Women with MS. , 2017, , 113-126.		0
586	Outcomes in Clinical Trials. , 2021, , 1-25.		0
587	CTNI-10. MAINTENANCE CHEMOTHERAPY USING BEVACIZUMAB FOR NEUROFIBROMATOSIS 2 PATIENTS WITH HEARING LOSS AND PROGRESSIVE VESTIBULAR SCHWANNOMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY (NF104). <i>Neuro-Oncology</i> , 2020, 22, ii43-ii43.	1.2	0
588	Randomized Trial Testing an Online Responsible Vendor Training in Recreational Marijuana Stores in the United States. <i>Journal of Studies on Alcohol and Drugs</i> , 2021, 82, 204-213.	1.0	0
589	Influence of Subject-Specific Effects in Longitudinal Modelling of Cognitive Decline in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-13.	2.6	0
590	Comparing the MSIS-29 and the Health Utilities Index Mark III in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2021, 12, 747853.	2.4	0